Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XAF5 Gel for Reduction of Submental Fat
NCT01990326Phase 2
Key facts
- Status
- Suspended
- Start
- Nov 2013
- Primary completion
- Jun 2014
- Sponsor
- Topokine Therapeutics
- Modality
- Small Molecules
- Drugs
- XAF5
- Conditions
- submental fat
01
Overview
Phase 2, randomised, double-blind trial in submental fat comparing XAF5 Gel with Placebo Gel (2 arms). Primary endpoint: Frequency of adverse events. Started Nov 2013; status: suspended.
02
Design
2 arms- Study design
- RandomizedDouble-blind
XAF5 Gel
Experimental arm receiving XAF5 Gel
Placebo Gel
Control arm receiving Placebo Gel
03
Who it enrols
Adults with moderate submental fat and minimal skin laxity, BMI < 40.
04
Endpoints
Primary
Frequency of adverse events
Beyond the preview
Go deeper on NCT01990326.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01990326.